-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING CORPORATION - ATEBIMETINIB PLUS MGNP SHOWS LONG SURVIVAL AND OUTSTANDING TOLERABILITY IN PHASE 2 PANCREATIC CANCER

Reuters·11/18/2026 12:32:44

Please log in to view news